Observational Study of Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Receiving BCRABL1 Inhibitors with Chemotherapy, Corticosteroids, or Monoclonal Antibodies

What this Trial Is About

This observational study focuses on adults aged 18 years and older diagnosed with Philadelphia chromosome positive Ph or BCRABL1 acute lymphoblastic leukemia ALL. It aims to collect real-world data on patients treated with a combination of BCRABL1 inhibitors alongside chemotherapy, corticosteroids, or monoclonal antibodies. The study is sponsored by Versailles Hospital and seeks to better understand treatment outcomes in this specific patient group. Participants have already received or are receiving treatment that combines BCRABL1 inhibitors with other therapies such as chemotherapy, corticosteroids, or monoclonal antibodies. This study observes these treatments without assigning any new interventions, focusing on the natural course and outcomes of this combined treatment approach in routine clinical care. Throughout the study, participants health and treatment responses are monitored over several years. Researchers will evaluate overall survival at 12 and 36 months, remission rates, molecular responses in bone marrow and blood, event-free and relapse-free survival, mutation incidence, treatment tolerance, and deaths during induction and remission. Data collection will involve regular assessments aligned with standard medical care, and participation may last until study completion in late 2027.

EWALL-PH OBSERVARTORY 2022